Navigation Links
YM BioSciences announces controlled equity offering
Date:4/26/2010

MISSISSAUGA, ON, April 26 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE YMI, TSX:YM), announced today that it has filed a prospectus supplement to its final base shelf prospectus, dated September 16, 2009, with the Ontario Securities Commission, and a supplement to its U.S. prospectus, dated September 16, 2009, forming part of its U.S. registration statement, with the United States Securities and Exchange Commission.

YM has entered into a Sales Agreement, dated April 23, 2010, with Cantor Fitzgerald & Co., under which YM may, at its discretion, from time to time sell up to a maximum of 7,750,000, of its common shares through an "at-the-market" equity offering program known as a Controlled Equity Offering ("CEO"). Cantor Fitzgerald & Co. will act as sales agent for any sales made under the CEO. The common shares will be sold at market prices prevailing at the time of a sale (if any) of the common shares or at prices negotiated with Cantor Fitzgerald & Co., and, as a result, prices may vary as between purchasers and during the period of the offering. The Company is not required to sell any of the reserved shares at any time during the term of the CEO, which extends until October 16, 2011, and there are no stand-by fees for having established the arrangement. The Sales Agreement does not prohibit the Company from conducting additional financings.

The Canadian prospectus and prospectus supplement have been filed on SEDAR and the U.S. prospectus and the supplement thereto have been filed on the SEC's website (

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
2. NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology
3. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
4. YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations
5. Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
6. YM BioSciences closes US$17.5 million financing
7. YM BioSciences to raise approximately US$15 million
8. Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference
9. TEI Biosciences PriMatrix(TM) Awarded Seal of Approval by American Podiatric Medical Association
10. YM BioSciences presents CYT387 and CYT997 data at international cancer conference
11. YM BioSciences granted two US patents for AeroLEF(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Gene synthesis and bioengineering company ... into a technology access and services agreement with ... proprietary protein engineering technology, known as “ProteinGPS®” to ... extremely excited that the global leader ADM has ... bioengineering technology has now been validated through many ...
(Date:12/17/2014)... Md. , Dec. 17, 2014 CASI ... company dedicated to the acquisition, development and commercialization of ... for the global market with a primary commercial focus ... it has been granted a Type C meeting with ... the meeting will be held in February 2015.  During ...
(Date:12/15/2014)... Israel , Dec. 15, 2014 /PRNewswire/ ... a leading developer of adult stem cell technologies for ... Therapeutics Ltd. was awarded a grant of approximately $1.1 ... the Chief Scientist (OCS).  This is the eighth year ... from the Office of the Chief Scientist, which is ...
(Date:12/15/2014)... COPENHAGEN, Denmark , Dec. 15, 2014 /PRNewswire/ ... its innovative TransCon technology to address significant unmet ... from its ongoing Phase 2 pediatric study to ... growth hormone deficiency, or GHD.  This interim analysis ... the anticipated total enrollment in the study, completing ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4
... the Annual Report to the Nation on the Status ... deaths for many types of cancers. This encouraging news can ... smoking and improved diet, and early detection. ... the blood cancers, early detection is rare, there are no ...
... Neb., April 1, 2011 Transgenomic, Inc. ... have completed studies employing the company,s high-sensitivity cancer ... and BLOCker™-Sequencing.  Results from these studies will be ... (AACR) meeting in Orlando, Florida, April 2-6, 2011. ...
... NY As part of the quest to form ... electronic, and medical devices, researchers at the U.S. Department ... molecules in thin films remain frozen at a temperature ... have a range of applications extending from organic solar ...
Cached Biology Technology:The Leukemia & Lymphoma Society: Accelerating Cures Must Be a Priority 2Transgenomic, Inc. Presentations to Describe High-Sensitivity Detection of Cancer Biomarkers at the 2011 American Association for Cancer Research Meeting 2Transgenomic, Inc. Presentations to Describe High-Sensitivity Detection of Cancer Biomarkers at the 2011 American Association for Cancer Research Meeting 3Transgenomic, Inc. Presentations to Describe High-Sensitivity Detection of Cancer Biomarkers at the 2011 American Association for Cancer Research Meeting 4Expanding the degrees of surface freezing 2
(Date:12/5/2014)... VIEW, Calif. , Dec. 4, 2014 /PRNewswire/ ... safety has boosted investments in new testing and ... has also given rise to a range of ... by the requirements of Generation Y, which is ... technologies. As a result, product development strategies of ...
(Date:12/3/2014)... -- As part of our commitment to offering the ... announce the release of a new reader that will ... data that they need. The Atlas 2000 ... readers. Many such devices have serious shortcomings when it ... models force users to navigate numerous complicated steps in ...
(Date:11/21/2014)... Nov. 20, 2014 C-Labs LLC, a leading ... of Things (IoT), today announced the appointment of ... officer. Previously a strategic advisor to the firm, Mr. ... Mr. Traynor is based out of the C-Labs office ... to Chris Muench , Chief Executive Officer. ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Inception Technologies to Release New Biometric Reader 2C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... been found to negatively affect these teenagers health in ... and cancers of the reproductive system. Given these findings, ... at increased risk for early puberty in order to ... youths., New research shows that greater support from mothers ...
... -- In response to the need for localized efforts ... threatened staghorn coral, Diego Lirman, Ph.D., and James Herlan, ... Marine and Atmospheric Science (RSMAS) have established an ... The goals of the coral nursery are to ...
... Inc.,(Pink Sheets: ESMT) ("e-Smart" or the "Company") responds ... in which a series of serious allegations,are made ... as untrue, inaccurate and misleading. IDsmart is operated ... plead guilty to,securities fraud charges in the U.S. ...
Cached Biology News:Family conditions may affect when girls experience puberty 2New south Florida nursery to focus on staghorn corals 2e-Smart Technologies Responds to Press Release Issued By IDsmart LLC 2e-Smart Technologies Responds to Press Release Issued By IDsmart LLC 3
Goat polyclonal to Glucose Dehydrogenase ( Abpromise for all tested applications). Antigen: Glucose Dehydrogenase (Bacillus species)...
Rabbit polyclonal to pCrosstide (HRP) ( Abpromise for all tested applications)....
Amyloid stain....
Phospho-Cyclin D1 (Thr286) Antibody...
Biology Products: